Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 12/20 | 0.63 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592486 | 0.84 | XPO1 (0.48) | XPO1NTRK1 | |
| SCHEMBL1592487 | 0.83 | XPO1 (0.43) | XPO1XDHADORA3ADORA2AADORA1 | |
| SCHEMBL3637557 | 0.78 | XPO1 (0.39) | XPO1TRPV1NTRK1 | |
| SCHEMBL1593000 | 0.74 | XPO1 (0.48) | XPO1TRPV1CYP11B2 | |
| SCHEMBL1593002 | 0.72 | XPO1 (0.44) | XPO1TRPV1CYP11B2 | |
| SCHEMBL24465012 | 0.71 | XPO1 (0.40) | XPO1NTRK1 | |
| SCHEMBL1592800 | 0.71 | XPO1 (0.48) | XPO1 | |
| SCHEMBL1592522 | 0.71 | XPO1 (0.47) | XPO1 | |
| SCHEMBL20880320 | 0.69 | XPO1 (0.46) | XPO1ADORA3ADORA2AADORA1 | |
| SCHEMBL29934305 | 0.68 | XDH (0.48) | XPO1XDHADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | MAVS, DDX18, ZC3HAV1 | XPO1 302/4885XDH 61/4885ADORA3 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.